If a patient's medication inhibits glycoprotein IIb/IIIa receptors on platelets, which consequence follows during an injury that causes bleeding?

💡 Explanation

Inhibition of glycoprotein IIb/IIIa receptors reduces platelet aggregation, because these receptors mediate platelet cross-linking via fibrinogen binding. Therefore, reduced platelet aggregation occurs, rather than increased thromboxane production or enhanced fibrinogen binding, which would promote clotting.

• If a researcher selectively inhibited GLP-1 receptor signaling in the arcuate nucleus of the hypothalamus, which consequence follows regarding appetite regulation?
• Why does increased blood flow velocity past a newly formed thrombus increase the risk of embolization?
• What causes increased susceptibility to infections when vitamin A deficiency impairs mucociliary clearance in the respiratory tract?
• Why does hepatic stellate cell activation exacerbate liver fibrosis following chronic alcohol exposure?
• Why does chronic activation of hepatic stellate cells occur during persistent insulin resistance?
• Which reduced feedback results when skin mechanoreceptors degrade?